Indoco Remedies Secures EU GMP Certification for Goa Manufacturing Facility
Indoco Remedies Limited has announced that its manufacturing facility for solid oral dosage form (Plant I) located in Goa has received EU GMP certification from the Malta Medicines Authority. This achievement follows an inspection conducted by the Malta Medicines Authority between November 19 and November 24, 2025.The certification confirms that the facility complies with Good Manufacturing Practice requirements as referenced in the EC Directive. The Goa plant is a key operational site within Indoco's network of pharmaceutical manufacturing facilities.
Commenting on this milestone, Ms. Aditi Panandikar, Managing Director of Indoco Remedies Ltd., stated that compliance is a core value driving the company's quality systems. She added that this approval reinforces their commitment to delivering the highest quality healthcare products to customers worldwide.
Company Overview and Operations
Indoco Remedies operates as a fully integrated, research oriented pharmaceutical company with a significant global presence. The organization maintains a turnover of US$ 175 million and employs over 6000 individuals, including more than 300 skilled scientists and field staff.
The company manages ten manufacturing facilities, six dedicated to Finished Dosage Forms (FDFs) and four for APIs (Active Pharmaceutical Ingredients). Its operations are supported by a state of the art Research and Development Centre and a CRO facility. Indoco's facilities have received approvals from regulatory bodies such as USFDA and UK-MHRA.
Indoco develops and manufactures a wide range of pharmaceutical products for both Indian and international markets. The company generates more than 109 million prescriptions annually, served by over 2,50,000 doctors across various specialties. Indoco possesses ten domestic marketing divisions and maintains a robust brand portfolio spanning therapeutic areas including Gastro-intestinal, Respiratory, Anti Infectives, Ophthalmic, Nutritionals, Cardiovascular, Anti Diabetics, Pain Management, Gynaecology, among others.
Top brands developed by the company include Cyclopam, Febrex Plus, ATM, Rexidin M, Karvol Plus, Oxipod, Cital, Sensodent K, and Homide. Internationally, Indoco has established tie ups with major generic companies across the globe.
INDOCO Stock Price Movement
Indoco Remedies Limited shares slipped on Thursday, closing down 2.61% to settle at ₹231.60 after shedding ₹6.20 from the previous close. The stock saw a trading range between a low of ₹229.50 and a high of ₹242.99 during the session, with 142,751 shares traded in total.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.